247 related articles for article (PubMed ID: 23759589)
21. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
[TBL] [Abstract][Full Text] [Related]
22. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
[TBL] [Abstract][Full Text] [Related]
23. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
24. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
26. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer.
Zhang Q; Chen X; Cao J; Yang W; Wan G; Feng Q; Zhou S; Yang H; Wang N; Liu Z; Xiao H; Zhu Y; Yu L
J Med Chem; 2023 Feb; 66(3):1725-1741. PubMed ID: 36692394
[TBL] [Abstract][Full Text] [Related]
28. Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.
Preston SEJ; Emond A; Pettersson F; Dupéré-Richer D; Abraham MJ; Riva A; Kinal M; Rys RN; Johnson NA; Mann KK; Del Rincón SV; Licht JD; Miller WH
Mol Cancer Ther; 2022 Apr; 21(4):511-521. PubMed ID: 35086959
[TBL] [Abstract][Full Text] [Related]
29. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.
Li H; Bitler BG; Vathipadiekal V; Maradeo ME; Slifker M; Creasy CL; Tummino PJ; Cairns P; Birrer MJ; Zhang R
Cancer Prev Res (Phila); 2012 Mar; 5(3):484-91. PubMed ID: 22144423
[TBL] [Abstract][Full Text] [Related]
30. Iron overload increases the sensitivity of endometriosis stromal cells to ferroptosis via a PRC2-independent function of EZH2.
Luo Y; Li L; Hu Q; Zhang Z; Liu F; Peng Y; Zou Y; Chen L
Int J Biochem Cell Biol; 2024 Apr; 169():106553. PubMed ID: 38417568
[TBL] [Abstract][Full Text] [Related]
31. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
32. Neighborhood matters: response to EZH2 methyltransferase inhibitors.
Gharpure KM; Sood AK
Cell Cycle; 2013 Aug; 12(15):2345. PubMed ID: 23887388
[No Abstract] [Full Text] [Related]
33. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
Xu L; Deng Q; Pan Y; Peng M; Wang X; Song L; Xiao M; Wang Z
Int J Mol Med; 2014 Jan; 33(1):91-6. PubMed ID: 24212330
[TBL] [Abstract][Full Text] [Related]
34. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
35. GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1α in human peritoneal mesothelial cells treated with high glucose.
Wang Q; Xu L; Zhang X; Liu D; Wang R
Eur J Pharmacol; 2020 Aug; 880():173076. PubMed ID: 32222493
[TBL] [Abstract][Full Text] [Related]
36. [Therapeutic effect of enhancer of Zeste homolog 2 inhibitor GSK343 on periodontitis by regulating macrophage differentiation].
Zhongchao W; Liyuan F; Dan T; Cong Z; Shijun L
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):264-268. PubMed ID: 28675010
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
[TBL] [Abstract][Full Text] [Related]
38. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]